May 27, 2020
Immutep Receives US$2.4 Million R&D Tax Incentive from French Government
May 25, 2020
Immutep Global Webcast to Present New Data from 2020 ASCO Annual Meeting
May 06, 2020
Immutep Granted Japanese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
Apr 29, 2020
Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting
Apr 28, 2020
Immutep Reports Positive Phase II TACTI-002 Data
Apr 20, 2020
Enrollment completed for the INSIGHT-004 Study
Immutep Quarterly Activities Report
Apr 14, 2020
Immutep Advances Cell Line Development for IMP761
Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020
Apr 08, 2020
Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer
Mar 24, 2020
Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020
Mar 18, 2020
Immutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti
Mar 08, 2020
Immutep Receives Second IND Approval for Efti from US FDA
Feb 18, 2020
Immutep Reports Positive TACTI-002 Data
Feb 04, 2020
Immutep to Present TACTI-002 Interim Data at German Cancer Congress
